Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT03257722 2024-02-28

PIL

Phase 1/2 Terminated

4 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT02440425 2022-10-07

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Phase 2 Completed

42 enrolled 14 charts

Gynecologic

Carcinoma, Ovarian Neoplasms, Recurrence

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Phase 1/2 Terminated

3 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02337491 2020-12-22

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Phase 2 Completed

80 enrolled 13 charts

CNS

Glioblastoma, Recurrence

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

48 enrolled 10 charts

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

PembroWM

HARBOUR

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

PIL

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Pembrolizumab +/- Bevacizumab for Recurrent GBM

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma